Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary
for tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who
have recurrent or progressive malignant glioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
North American Brain Tumor Consortium Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins